Shares of Autolus Therapeutics plc (NASDAQ:AUTL) have been assigned an average recommendation of “Buy” from the ten brokerages that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $21.71.
A number of equities research analysts have recently issued reports on AUTL shares. Zacks Investment Research lowered Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 2nd. HC Wainwright lowered their target price on Autolus Therapeutics from $19.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, January 7th. JPMorgan Chase & Co. lowered Autolus Therapeutics from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $24.00 to $9.00 in a research note on Friday, January 29th. Redburn Partners reissued a “neutral” rating on shares of Autolus Therapeutics in a report on Tuesday, March 16th. Finally, Truist reduced their price target on Autolus Therapeutics from $30.00 to $15.00 in a report on Thursday, January 7th.
Institutional investors and hedge funds have recently modified their holdings of the stock. State Street Corp boosted its holdings in Autolus Therapeutics by 115.4% in the third quarter. State Street Corp now owns 24,267 shares of the company’s stock valued at $282,000 after purchasing an additional 12,999 shares during the last quarter. Pendal Group Limited bought a new position in Autolus Therapeutics during the 4th quarter worth approximately $450,000. Baker BROS. Advisors LP lifted its holdings in Autolus Therapeutics by 69.6% during the 4th quarter. Baker BROS. Advisors LP now owns 782,183 shares of the company’s stock worth $6,993,000 after buying an additional 320,859 shares during the last quarter. California Public Employees Retirement System lifted its holdings in Autolus Therapeutics by 3.2% during the 3rd quarter. California Public Employees Retirement System now owns 41,500 shares of the company’s stock worth $483,000 after buying an additional 1,300 shares during the last quarter. Finally, Schroder Investment Management Group lifted its holdings in Autolus Therapeutics by 6.8% during the 4th quarter. Schroder Investment Management Group now owns 1,672,732 shares of the company’s stock worth $14,954,000 after buying an additional 107,082 shares during the last quarter. 22.86% of the stock is owned by hedge funds and other institutional investors.
Autolus Therapeutics (NASDAQ:AUTL) last posted its earnings results on Wednesday, March 3rd. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.06). Autolus Therapeutics had a negative net margin of 8,652.90% and a negative return on equity of 54.01%. The company had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.43 million. As a group, research analysts expect that Autolus Therapeutics will post -2.69 EPS for the current fiscal year.
About Autolus Therapeutics
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer.
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.